Company: University of Birmingham
Job title: Director, Precision Medicine Trials
Dr Sharpe takes a lead on precision medicine within the University of Birmingham Cancer Research Clinical Trials Unit, looking after four early phase clinical and trials teams as well as the broader precision medicine strategy. Within this, she looks to increase the emphasis on sample acquisition/optimisation of testing as well as the introduction of novel and innovative trial methodology.
She has a particular interest in increasing the link between early phase clinical trials and reverse translating links between patient outcome and tumour biology.
Before starting her current role, Dr Sharpe was the Head of Precision Medicine at Cancer Research UK, where she had responsibility for leading on the Charity’s agenda in this area and delivering on/evolving the CRUK Stratified Medicine Programme (SMP). The CRUK SMP is a nation-wide genomic screening study which both determines trial eligibility but also aims to improve sample standards, performance of genomic sequencing and the utilisation of these results across the UK as a whole.
Prior to this, Dr. Sharpe worked at the Royal Marsden NHS Foundation Trust as their NIHR BRC Assistant Director where she set up a new method for awarding and monitoring funding internally, set up the new Royal Marsden Clinical Trials Unit, oversaw the Generic Biobank and led on Royal Marsden involvement in initiatives such as Genomics England.
Dr. Sharpe has also carried out large change programmes, for example with the Children’s Cancer and Leukaemia Group (CCLG), overseen the management of early phase trial grants and carried out several strategic reviews at CRUK, including the future of biomarker-driven clinical trials